跳至主要内容
临床试验/JPRN-jRCT2031210297
JPRN-jRCT2031210297进行中(未招募)3 期

Efficacy and safety of oral semaglutide 50 mg once daily in subjects with overweight or obesity - OASIS 1

ishida Hiroko0 个研究点目标入组 60 人开始时间: 2021年9月7日最近更新:
适应症

试验速览

阶段
3 期
状态
进行中(未招募)
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • 1. Male or female, age >= 18 years at the time of signing informed consent
  • 2. Body mass index (BMI):
  • a) >=27.0 kg/m2 with the presence of at least one of the following weight-related complications (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease
  • b)>= 30.0 kg/m2
  • 3. History of at least one self-reported unsuccessful dietary effort to lose body weight

排除标准

  • 1. HbA1c >=6.5% (48 mmol/mol) as measured by the central laboratory at screening
  • 2. A self-reported change in body weight > 5 kg (11 lbs) within 90 days before screening irrespective of medical records

研究者

发起方
ishida Hiroko

相似试验